JP2023537958A5 - - Google Patents

Info

Publication number
JP2023537958A5
JP2023537958A5 JP2023509554A JP2023509554A JP2023537958A5 JP 2023537958 A5 JP2023537958 A5 JP 2023537958A5 JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023509554 A JP2023509554 A JP 2023509554A JP 2023537958 A5 JP2023537958 A5 JP 2023537958A5
Authority
JP
Japan
Application number
JP2023509554A
Other languages
Japanese (ja)
Other versions
JPWO2022037527A5 (https=
JP7821159B2 (ja
JP2023537958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/112756 external-priority patent/WO2022037527A1/zh
Publication of JP2023537958A publication Critical patent/JP2023537958A/ja
Publication of JPWO2022037527A5 publication Critical patent/JPWO2022037527A5/ja
Publication of JP2023537958A5 publication Critical patent/JP2023537958A5/ja
Application granted granted Critical
Publication of JP7821159B2 publication Critical patent/JP7821159B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023509554A 2020-08-20 2021-08-16 Bcmaと結合する単一可変ドメイン及び抗原結合分子 Active JP7821159B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010842370 2020-08-20
CN202010842370.5 2020-08-20
PCT/CN2021/112756 WO2022037527A1 (zh) 2020-08-20 2021-08-16 结合bcma的单可变结构域及抗原结合分子

Publications (4)

Publication Number Publication Date
JP2023537958A JP2023537958A (ja) 2023-09-06
JPWO2022037527A5 JPWO2022037527A5 (https=) 2024-08-26
JP2023537958A5 true JP2023537958A5 (https=) 2024-08-26
JP7821159B2 JP7821159B2 (ja) 2026-02-26

Family

ID=80323410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509554A Active JP7821159B2 (ja) 2020-08-20 2021-08-16 Bcmaと結合する単一可変ドメイン及び抗原結合分子

Country Status (5)

Country Link
EP (1) EP4202047A4 (https=)
JP (1) JP7821159B2 (https=)
KR (1) KR20230045066A (https=)
CN (1) CN115715325A (https=)
WO (1) WO2022037527A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282877A3 (en) 2016-08-10 2024-02-21 Legend Biotech Ireland Limited Chimeric antigen receptors targeting bcma and methods of use thereof
BR112020006248A8 (pt) * 2017-09-29 2023-03-21 Mogam Inst Biomedical Res Anticorpo anti-bcma com alta afinidade para bcma, polinucleotídeo, vetor de expressão, célula hospedeira, método para produção do dito anticorpo, composição farmacêutica compreendendo o mesmo e uso do anticorpo para prevenção ou tratamento de câncer
UY38251A (es) * 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3845244A4 (en) * 2018-08-24 2022-09-07 Shenzhen Pregene Biopharma Co. Ltd. ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE
CN109942708B (zh) * 2019-03-28 2021-01-05 上海科棋药业科技有限公司 一种抗bcma的单域抗体及其应用
CN109942709B (zh) * 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
CN111333729B (zh) * 2020-03-17 2022-12-06 深圳市南科生物工程有限公司 抗b细胞成熟抗原的纳米抗体及应用
CN117062840A (zh) * 2021-04-15 2023-11-14 正大天晴药业集团股份有限公司 靶向bcma的多特异性抗体

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)